#Singapore #Brain Disorders #Neurophet #Raffles Medical

Neurophet AQUA: A Game-Changer in Neuroimaging

In a significant advancement for medical diagnostics, Neurophet, co-led by Jake Junkil Been and Donghyeon Kim, has announced the supply of its innovative AI-driven software, Neurophet AQUA, to Raffles Medical in Singapore. This partnership is set to enhance the evaluation and treatment of neurodegenerative diseases such as Alzheimer’s and vascular dementia.

What is Neurophet AQUA?

Neurophet AQUA is a state-of-the-art neurodegenerative brain imaging analysis tool designed for ultra-fast, quantitative assessments of MRI scans. It offers accurate measurements of brain atrophy and white matter degeneration, critical factors in diagnosing conditions that affect cognitive health. This software empowers healthcare professionals to generate tailored analysis reports, facilitating more personalized treatment plans for individual patients.

The Role of Raffles Medical

Raffles Medical is the flagship healthcare provider of the Raffles Medical Group, which operates over 100 clinics across Singapore and the wider Asian region. The integrated healthcare model of Raffles Medical ensures that patients have seamless access to specialist services, making it an ideal partner for the implementation of advanced diagnostic tools like Neurophet AQUA.

Jake Junkil Been, Co-CEO of Neurophet, expressed enthusiasm over this collaboration, stating, "We are very pleased to supply Neurophet's products to Raffles Medical, following successful engagements with prestigious institutions such as the Dementia Research Centre at Nanyang Technological University and Singapore General Hospital."

Significance of the Collaboration

This partnership marks a crucial step in the integration of advanced artificial intelligence technology into clinical environments, ultimately aimed at improving patient outcomes. By facilitating quicker and more accurate analysis of brain health, Neurophet AQUA is expected to play a pivotal role in diagnosing and monitoring brain disorders effectively.

About Neurophet

Founded in 2016, Neurophet specializes in crafting AI-powered solutions intended to support the diagnosis and treatment of brain-related disorders. The company's extensive product line includes not only Neurophet AQUA but also tools like

• - Neurophet SCALE PET: A software for PET image quantitative analysis.
• - Neurophet tES/TMS LAB: Provides treatment planning for brain stimulation therapies.
• - Neurophet AQUA AD: Focused on Alzheimer's treatment monitoring.
• - Neurophet AQUA MS: Targets image analysis for multiple sclerosis.

Through continuous innovation, Neurophet is committed to addressing the challenges faced in neurodiagnostics. The company's vision is to leverage the power of AI to enhance health outcomes for patients suffering from cognitive disorders, harnessing expertise in neuroscience and technology.

As it collaborates with institutions like Raffles Medical, Neurophet not only aims to refine the diagnostic process but also aspires to contribute to the larger narrative surrounding mental health and brain health advancements, paving the way for transformative medical solutions.

In summary, the supply of Neurophet AQUA to Raffles Medical underscores a notable leap forward in healthcare technology, promising to make significant strides in the battle against neurodegenerative diseases. As the collaboration unfolds, it will be exciting to observe how this technology influences clinical practices and patient care in the neurohealth sector.